OBJECTIVES: In the current study we describe cytogenetic findings as well as clinical correlates and long-term prognostic relevance of abnormal cytogenetics at the time of diagnosis of essential thrombocythemia (ET). PATIENTS AND METHODS: The study cohort consisted of a consecutive group of patients with ET who fulfilled the World Health Organization diagnostic criteria, and in whom cytogenetic analysis was performed at diagnosis. RESULTS: A total of 402 patients were studied (median age, 56 yrs; median follow-up 70 months). The prevalence of abnormal cytogenetics at diagnosis was 7% (28 of 402). The most common cytogenetic anomalies were trisomy 9 (four patients), abnormal chromosome 1 (three patients) and trisomy 8 (two patients). Parameters at diagnosis that were significantly associated with abnormal cytogenetics included palpable splenomegaly (P = 0.03), current tobacco use (P = 0.04); venous thrombosis (P = 0.02), and anemia with a hemoglobin of <10 g/dL (P = 0.02); but did not include JAK2V617F mutation status, or advanced age. During follow up, patients with abnormal cytogenetics did not have shorter survival, or increased transformation to acute leukemia or myelofibrosis. CONCLUSION: Cytogenetic anomalies at diagnosis are relatively uncommon in ET, and do not predict evolution into more aggressive myeloid disorders, or inferior survival.
OBJECTIVES: In the current study we describe cytogenetic findings as well as clinical correlates and long-term prognostic relevance of abnormal cytogenetics at the time of diagnosis of essential thrombocythemia (ET). PATIENTS AND METHODS: The study cohort consisted of a consecutive group of patients with ET who fulfilled the World Health Organization diagnostic criteria, and in whom cytogenetic analysis was performed at diagnosis. RESULTS: A total of 402 patients were studied (median age, 56 yrs; median follow-up 70 months). The prevalence of abnormal cytogenetics at diagnosis was 7% (28 of 402). The most common cytogenetic anomalies were trisomy 9 (four patients), abnormal chromosome 1 (three patients) and trisomy 8 (two patients). Parameters at diagnosis that were significantly associated with abnormal cytogenetics included palpable splenomegaly (P = 0.03), current tobacco use (P = 0.04); venous thrombosis (P = 0.02), and anemia with a hemoglobin of <10 g/dL (P = 0.02); but did not include JAK2V617F mutation status, or advanced age. During follow up, patients with abnormal cytogenetics did not have shorter survival, or increased transformation to acute leukemia or myelofibrosis. CONCLUSION: Cytogenetic anomalies at diagnosis are relatively uncommon in ET, and do not predict evolution into more aggressive myeloid disorders, or inferior survival.
Authors: Barbara Mora; Toni Giorgino; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Barraco; Michele Merli; Daniela Pietra; Rosario Casalone; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Francesco Passamonti Journal: Haematologica Date: 2018-04-05 Impact factor: 9.941
Authors: Rosane Isabel Bittencourt; Jose Vassallo; Maria de Lourdes Lopes Ferrari Chauffaille; Sandra Guerra Xavier; Katia Borgia Pagnano; Ana Clara Kneese Nascimento; Carmino Antonio De Souza; Carlos Sergio Chiattone Journal: Rev Bras Hematol Hemoter Date: 2012
Authors: Leonardo Caires Dos Santos; Juliana Corrêa da Costa Ribeiro; Neusa Pereira Silva; Janete Cerutti; Maria Regina Regis da Silva; Maria de Lourdes Lopes Ferrari Chauffaille Journal: Rev Bras Hematol Hemoter Date: 2011
Authors: Jae Ryuk Kim; Young Uk Cho; Mi Hyun Bae; Bohyun Kim; Seongsoo Jang; Eul Ju Seo; Hyun Sook Chi; Chan Jeoung Park Journal: Ann Lab Med Date: 2016-07 Impact factor: 3.464